Length of Follow-up Time for New Users of Immunosuppressive Drugs

Project Title Length of Follow-up Time for New Users of Immunosuppressive Drugs
Date Posted
Wednesday, February 28, 2018
Project ID
cder_mpl1p_wp006_nsdp_v01
Status
Complete
Deliverables
Description

This report contains estimates of the length of follow-up time for new users of immunosuppressive drugs (adalimumab, alemtuzumab, certolizumab, dalfampridine, dimethyl fumarate, etanercept, fingolimod, glatiramer acetate, golimumab, infliximab, interferon beta-1A, interferon beta-1B, mitoxantrone, natalizumab, pegylated intereferon beta-1A, teriflunomide, and ustekinumab) and for patients diagnosed with Crohn's disease, multiple sclerosis, psoriasis, and ulcerative colitis in the Sentinel Distributed Database (SDD). This report was distributed to Data Partners on June 30, 2017. 

Medical Product
adalimumab
alemtuzumab
certolizumab
dalfampridine
dimethyl fumarate
etanercept
fingolimod
glatiramer acetate
golimumab
infliximab
interferon beta-1A
interferon beta-1B
mitoxantrone
natalizumab
pegylated interferon beta-1A
teriflunomide
ustekinumab
Population / Cohort
Individuals 18 years of age or older
Time Period
January 1, 2000 - June 30, 2017
Assessment Type
Exploratory Analyses
Study Type
Modular Program
Data Sources
Sentinel Distributed Database (SDD)
FDA Center
CDER